Dabigatran etexilate-d13 is intended for use as an internal standard for the quantification of dabigatran etexilate by GC- or LC-MS. Dabigatran etexilate is a double prodrug that undergoes in vivo hydrolytic cleavage to produce dabigatran , a potent thrombin inhibitor (Ki = 4.5 nM).1,2 Dabigatran etexilate shows antithrombotic efficacy in animal models of thrombosis, with a rapid onset of action.2 It is not metabolized by cytochrome P450 isozymes and has a low potential for drug-drug interactions.
1.Hauel, N.H., Nar, H., Priepke, H., et al.Structure-based design of novel potent nonpeptide thrombin inhibitorsJ. Med. Chem.45(9)1757-1766(2002) 2.Eisert, W.G., Hauel, N., Stangier, J., et al.Dabigatran: An oral novel potent reversible nonpeptide inhibitor of thrombinArterioscler. Thromb. Vasc. Biol.30(10)1885-1889(2010)